Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:34 PM
Ignite Modification Date: 2025-12-24 @ 11:34 PM
NCT ID: NCT06948656
Eligibility Criteria: Inclusion criteria: * Age ≥18 years * Person with oral consent * Patient with cirrhosis according to the 2021 EASL criteria (1) * Patient receiving regular six-monthly and systematic monitoring of cirrhosis, according to the European recommendations of the EASL (2), or French recommendations of the TNCD (3) and HAS (4), including a clinical examination, a biological work-up (to calculate the CHILD-PUGH score and monitor alpha-feto-protein), AND requiring imaging to screen for HCC of hepatocellular carcinoma using cross-sectional imaging (by MRI and/or hepatic CT scan). Exclusion Criteria: * Patients with active cancer or treated within the last 6 months * Patient with an acute episode of cirrhosis decompensation (ongoing antibiotic treatment for an active infection, gastrointestinal bleeding, hepatic encephalopathy, acute alcoholic hepatitis) less than one month old. * Treatment with systemic corticosteroids, in progress or within the last 3 months * Patient with organ transplant * Person not affiliated to or not benefiting from a social security scheme * Person under legal protection (curatorship, guardianship) * Person subject to a legal protection measure * Pregnant or breast-feeding women * An adult who is incapable or unable to give consent * Minors * Patients already included in an interventional study who may interfere with the evaluation of this study.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT06948656
Study Brief:
Protocol Section: NCT06948656